Chai Discovery | $70,000,000 | (Aug 7, 2025)
Xovian Aerospace | $2,500,000 | (Aug 7, 2025)
Elion | $9,300,000 | (Aug 7, 2025)
Certified by Founder
Lodge
Bolden Therapeutics
start up
United States
- Providence, Rhode Island
- 10/01/2024
- Unknown
- Undisclosed Amount
Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.
- Industry Biotechnology Research
- Website https://www.boldentherapeutics.com/
- LinkedIn https://www.linkedin.com/company/bolden-therapeutics/about/
August | $7,000,000 | (Aug 7, 2025)
Stavtar Solutions | $55,000,000 | (Aug 7, 2025)
Tavily | $25,000,000 | (Aug 7, 2025)
Clay | $100,000,000 | (Aug 7, 2025)
Tracelight | $3,600,000 | (Aug 7, 2025)
CodeKarma | $2,500,000 | (Aug 7, 2025)
WiseBee | $2,444,263 | (Aug 7, 2025)
Positive Development | $51,500,000 | (Aug 7, 2025)
Vendict | $10,000,000 | (Aug 6, 2025)